{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(14)"],"submitter":["Tachita T"],"pubmed_abstract":["Multiple myeloma (MM) is an incurable B-cell malignancy often accompanied by profound immunodeficiency. Lenalidomide (Len) is an immunomodulatory drug that exerts promising therapeutic effects on MM through the immune system. However, predictive markers related to the effects of Len treatment are not fully understood. This study aimed to identify candidate biomarkers for predicting the clinical efficacy of Len and dexamethasone (Ld) therapy through a comprehensive analysis of serum cytokines. The levels of 48 cytokines in the serum of patients with MM just before Ld therapy (n = 77), at the time of best response (n = 56), and at disease progression (n = 49) were measured and evaluated. Patients with high IL-18 and M-CSF levels showed significantly shorter progression-free survival and over"],"journal":["Cancer medicine"],"pagination":["e70019"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11259000"],"repository":["biostudies-literature"],"pubmed_title":["Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone."],"pmcid":["PMC11259000"],"pubmed_authors":["Kusumoto S","Ri M","Aoki S","Asano A","Komatsu H","Asao Y","Narita T","Kanamori T","Totani H","Iida S","Kinoshita S","Masaki A","Tachita T","Ito A"],"additional_accession":[]},"is_claimable":false,"name":"Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone.","description":"Multiple myeloma (MM) is an incurable B-cell malignancy often accompanied by profound immunodeficiency. Lenalidomide (Len) is an immunomodulatory drug that exerts promising therapeutic effects on MM through the immune system. However, predictive markers related to the effects of Len treatment are not fully understood. This study aimed to identify candidate biomarkers for predicting the clinical efficacy of Len and dexamethasone (Ld) therapy through a comprehensive analysis of serum cytokines. The levels of 48 cytokines in the serum of patients with MM just before Ld therapy (n = 77), at the time of best response (n = 56), and at disease progression (n = 49) were measured and evaluated. Patients with high IL-18 and M-CSF levels showed significantly shorter progression-free survival and over","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-26T22:21:34.937Z","creation":"2025-04-06T17:13:14.893Z"},"accession":"S-EPMC11259000","cross_references":{"pubmed":["39031503"],"doi":["10.1002/cam4.70019"]}}